Table 4.

Depressive disorder studies.

Study	Population	Design	Substance and dose	N	Short-term results	Long-term follow-up
Aust et al. (48)	Adult inpatients with MDD	UOLS	Ketamine (0.5 mg/kg over 40 min), three infusions per week for 2 weeks.	31	Significant difference on 5D-ASC subscale ‘anxious ego-disintegration' for responders (≥ 50% MADRS reduction), with no significant difference in the other 4 dimensions after final dose	N/A
Carhart-Harris et al. (16)*	Adult patients with TRD	UOLS	Psilocybin (10 and 25 mg), two doses, 7 days apart	20	Significant association between mean USB score and decrease in QIDS-SR16. USB, dimensions of 11D-ASC, as a significant predictor of clinical outcome at week 5	6 months: Changes sustained
Roseman et al. (14)*	[As above]	UOLS	[As above]	20	From baseline to week 5: significant long-term positive therapeutic outcome (reduction in QIDS-SR16) following higher occurrence and magnitude of OBN and DED OBN, compared to VRS and AUA, is a significantly better predictor of therapeutic outcome “Complete” OBN leads to better clinical outcomes	N/A
Palhano-Fontes et al. (47)	Adult patients with TRD	RCT	Ayahuasca (1 ml/kg), single dose	29	Significant positive correlation between MADRS score changes on day 7 with the HRS subscale 'perception,' and significant negative correlation with the MEQ subscale ‘transcendence of time and space'	N/A

MDD, Major Depressive Disorder; TRD, Treatment-resistant Depression; UOLS, Uncontrolled Open-Label Study; RCT, Randomized Controlled Trials; 5D-ASC, 5 Dimensions of Altered States of Consciousness Scale; MADRS, Montgomery-Asberg Depression Rating Scale; HRS, Hallucinogenic Rating Scale; USB, Unity, Spiritual Experience, and Blissful state; QIDS, Quick Inventory of Depressive Symptomatology; 11D-ASC, 11 Dimensions of Altered States of Consciousness Scale; OBN, Oceanic Boundlessness; DED, Dread of Ego Dissolution; VRS, Visionary Restructuralization; AUA, Auditory Alterations; VIR, Vigilance Reduction.

* Studies with same population.